Award
NIH Reporter #5R41DK142311-02
Restoring Tolerance in Inflammatory Bowel Disease with an Oral AMPK agonist Nanomedicine that Targets Antigen Presenting Cells
Recipient
Not specified
Award Amount
$302,409.00
Ceiling
$302,409.00
Awarded
August 25, 2025
Identifier
5R41DK142311-02
NIH awarded a grant to develop an oral nanomedicine targeting antigen presenting cells for treating inflammatory bowel disease, with a project duration of nearly three years and funding of approximately $302,409.
Description
The project aims to develop a first-in-class, oral, APC-specific nanotherapy for IBD involving nanoparticle formulation of PF-739 (QR401) for targeted delivery. Funded by NIH grant PA-23-232, the project duration is from September 20, 2024, to July 31, 2027.